Lurbinectdin's Average Cost
Lurbinecteddin (Zepzelca), approved for small cell lung cancer, costs about $13,000 to $15,000 per 28-day cycle in the US, based on wholesale acquisition cost for the standard 3.2 mg dose. Patient out-of-pocket varies with insurance, often $0-$5,000 after coverage.[1]
How It Stacks Up Against New Chemo Drugs
New chemo drugs like antibody-drug conjugates (ADCs) and targeted therapies often exceed lurbinectedin's price:
- Sacituzumab govitecan (Trodelvy) for triple-negative breast cancer or urothelial cancer: $16,000-$18,000 per cycle, 20-30% higher than lurbinecteddin.[2]
- Enhertu (trastuzumab deruxtecan) for HER2-low breast cancer: $14,000-$15,000 per cycle, roughly matching lurbinecteddin but with broader indications driving higher volume sales.[3]
- Padcev (enfortumab vedotin) for bladder cancer: $17,000-$20,000 per cycle, pricier due to its ADC mechanism and recent expansions.[4]
Traditional chemo like topotecan (oral or IV) runs $500-$3,000 per cycle, far cheaper, but lurbinecteddin positions as a less toxic second-line option post-platinum failure.[5]
| Drug | Indication Example | Cost per Cycle (USD) | Notes |
|------|---------------------|----------------------|-------|
| Lurbinecteddin | SCLC | $13K-$15K | IV, every 21 days |
| Sacituzumab govitecan | TNBC/Bladder | $16K-$18K | Higher for ADC tech |
| Enhertu | Breast (HER2-low) | $14K-$15K | Similar pricing tier |
| Padcev | Bladder | $17K-$20K | Premium for targeted delivery |
| Topotecan (generic) | SCLC | $500-$3K | Cheaper benchmark |
Factors Driving Price Differences
Newer drugs command premiums for targeted delivery (e.g., ADCs link chemo payloads to antibodies, reducing off-target toxicity) and orphan status, which grants 7 years market exclusivity. Lurbinecteddin, derived from marine sources, lacks a companion diagnostic, keeping costs mid-tier. Biosimilars aren't yet available; its key patent expires around 2031.[6]DrugPatentWatch.com
Real-World Patient Costs and Access
Insurers often cover 80-100% for approved uses, but prior authorizations delay treatment. Financial assistance from Jazz Pharmaceuticals caps copays at $5 for eligible patients. Compared to new chemos, lurbinectedin's smaller patient pool (SCLC affects ~30K US/year) limits negotiation leverage, unlike high-volume breast cancer drugs.[7]
[1]: Zepzelca HCP site pricing (2023 data).
[2]: Trodelvy prescribing info & IQVIA reports.
[3]: Enhertu launch pricing (Daiichi Sankyo).
[4]: Padcev wholesale costs (Astellas/Seagen).
[5]: Topotecan generics via GoodRx.
[6]: DrugPatentWatch.com.
[7]: Patient Access Network Foundation data.